When should metoprolol succinate (extended‑release) be used instead of metoprolol tartrate (immediate‑release), and what are the dosing differences?

Metoprolol Succinate vs Tartrate: Clinical Selection and Dosing

Direct Answer

Metoprolol succinate (extended-release) should be used instead of metoprolol tartrate (immediate-release) in all patients with heart failure, as only succinate has proven mortality benefit; tartrate has never demonstrated mortality reduction in heart failure trials and should not be used as a substitute. 1, 2

---

Evidence-Based Formulation Selection

Heart Failure (HFrEF)

• Only metoprolol succinate 200 mg once daily is the evidence-based formulation with proven mortality reduction in heart failure patients. 2
• Metoprolol tartrate (immediate-release) has never demonstrated mortality benefit in heart-failure trials; it was merely the comparator arm in the COMET trial and is not guideline-recommended. 2
• The 2022 ACC/AHA/HFSA heart failure guidelines specifically recommend sustained-release metoprolol succinate as one of only three beta-blockers (along with bisoprolol and carvedilol) proven to reduce mortality in HFrEF. 1
• Beta-blockers cannot be considered interchangeable on a class-effect basis; only the three mortality-proven agents should be used. 2

Hypertension and Angina

• For hypertension and angina, either formulation is acceptable, but when switching from tartrate to succinate, use the same total daily dose. 3
• Metoprolol succinate provides once-daily dosing convenience with more stable 24-hour blood pressure and heart rate control compared to tartrate's multiple daily doses. 4, 5

---

Pharmacokinetic and Pharmacodynamic Differences

Metoprolol Succinate (Extended-Release)

• Delivers metoprolol at a near-constant rate for approximately 20 hours, producing even plasma concentrations over 24 hours without marked peaks and troughs. 5
• Maintains consistent beta1-blockade throughout the entire 24-hour dosing interval while preserving cardioselectivity at doses up to 200 mg daily. 3, 5
• Produces three- to fourfold higher trough concentrations and considerably lower peak plasma levels compared to immediate-release formulation. 6
• The controlled-release mechanism involves multiple-unit pellets that each act as diffusion cells, releasing drug over approximately 20 hours independent of food intake and gastrointestinal pH. 5, 7

Metoprolol Tartrate (Immediate-Release)

• Produces significantly larger peak effects on exercise tachycardia but effects are not evident at 24 hours with once-daily dosing. 3
• Requires three to four times daily dosing to match the peak-to-trough ratio achieved with succinate extended-release over the 200-400 mg dosing range. 3
• 50 mg tartrate three times daily produces peak plasma levels comparable to 200 mg succinate once daily (285 vs 263 nmol/L), but with much greater fluctuation. 8

---

Dosing Protocols by Indication

Heart Failure Initiation and Titration

• Starting dose: 25 mg once daily for NYHA Class II heart failure; 12.5 mg once daily for more severe heart failure (NYHA Class III-IV). 3
• Titration schedule: Double the dose every 2 weeks as tolerated, targeting 200 mg once daily maximum. 2, 3
• Prior to initiation, stabilize dosing of diuretics, ACE inhibitors, and digitalis (if used). 3
• If transient worsening of heart failure occurs, increase diuretics first before reducing beta-blocker dose; temporary discontinuation may be necessary but attempt re-titration later. 3
• For symptomatic bradycardia, reduce the metoprolol succinate dose rather than discontinue. 3

Hypertension

• Initial dose: 25-100 mg once daily, whether used alone or with a diuretic. 3
• Titrate at weekly intervals until optimal blood pressure reduction is achieved; maximum effect of any dose level appears after 1 week. 3
• Maximum studied dose: 400 mg daily; doses above this have not been evaluated. 3

Angina Pectoris

• Initial dose: 100 mg once daily. 3
• Titrate gradually at weekly intervals until optimal clinical response or pronounced heart rate slowing occurs. 3
• Maximum studied dose: 400 mg daily. 3
• If discontinuing treatment, reduce dose gradually over 1-2 weeks to avoid rebound angina or myocardial infarction. 3

---

Conversion Between Formulations

Tartrate to Succinate Conversion

• For hypertension and angina: Use the same total daily dose when switching from immediate-release tartrate to extended-release succinate. 3
• Example: Metoprolol tartrate 50 mg twice daily (100 mg total) converts to metoprolol succinate 100 mg once daily. 3
• For heart failure: Do not convert tartrate to succinate—tartrate should be replaced entirely with succinate using the heart failure initiation protocol (start 12.5-25 mg once daily, titrate every 2 weeks to 200 mg). 2

Bioequivalence Considerations

• A 100 mg metoprolol succinate tablet contains 95 mg of metoprolol succinate salt and is considered equivalent in activity to 100 mg metoprolol tartrate. 7
• Despite equivalent total beta1-blockade over 24 hours (area under the curve), succinate produces 20% lower relative bioavailability but more effective plasma concentration utilization. 4, 6

---

Critical Monitoring Parameters

During Initiation and Titration

• Heart failure symptoms and fluid status—increase diuretics or ACE inhibitors before reducing beta-blocker if symptoms worsen. 2
• Symptomatic hypotension—watch for systolic blood pressure <85 mmHg. 2
• Symptomatic bradycardia—monitor heart rate; adjust dose if clinically significant. 2
• Renal function—assess creatinine/eGFR for deterioration during titration. 2

Steady-State Effects

• Metoprolol succinate 200 mg produces more pronounced suppression of 24-hour heart rate compared to tartrate 50 mg three times daily, with better maintenance of effect at trough (24 hours post-dose). 8
• Exercise heart rate reduction at peak/trough for succinate: 14%/9% at 50 mg, 16%/10% at 100 mg, 24%/14% at 200 mg, 27%/22% at 300 mg, and 27%/20% at 400 mg once daily. 3

---

Common Pitfalls and How to Avoid Them

Formulation Substitution Error

• Never substitute metoprolol tartrate for succinate in heart failure patients—this removes proven mortality benefit. 2
• Verify the specific formulation prescribed: succinate is the extended-release, once-daily formulation; tartrate is immediate-release, multiple-daily-dose formulation. 2

Abrupt Discontinuation

• Never abruptly discontinue any beta-blocker—sudden withdrawal can precipitate angina, myocardial infarction, or life-threatening arrhythmias. 2, 3
• Taper gradually over 1-2 weeks when discontinuation is necessary. 3

Inadequate Titration in Heart Failure

• Initial difficulty with titration should not preclude later attempts to introduce or up-titrate metoprolol succinate. 3
• Target the evidence-based dose of 200 mg once daily rather than settling for subtherapeutic doses; mortality benefit is dose-related. 1, 2

Tablet Administration

• Metoprolol succinate tablets are scored and can be divided, but the whole or half tablet must be swallowed whole—never chewed or crushed, as this destroys the extended-release mechanism. 3